Clinical trials: Atopic Dermatitis / Eczema
Atopic Dermatitis
Study of CM310 Injection in Adolescent Subjects With Atopic Dermatis
This is a multi-center, randomized, double blind, placebo-controlled phase 3 study to evaluate the efficacy, safety, pharmacokinetics(PK), pharmacodynamics(PD) and immunogenicity of CM310 in children patients with…
- Trial name
- NCT06277765
- Testing
- CM310
- Where
- China
- Volunteers
- 180 people
- Sponsor
- Keymed Biosciences Co.Ltd
Atopic Dermatitis
Study To Evaluate Pf-04965842 In Subjects With Moderate To Severe Atopic Dermatitis
Study B7451006 is a Phase 2b POC study which is planned to assess four PF 04965842 once daily (QD) doses (10, 30, 100, 200 mg) relative to placebo over 12 weeks to characterize the efficacy and safety of PF 04965842 in subjects…
- Trial name
- NCT02780167
- Testing
- PF-04965842
- Where
- 64 sites in United States, Australia and 3 more
- Volunteers
- 269 people
- Sponsor
- Pfizer
Atopic Dermatitis
Efficacy and Safety Study of Orally Administered DS107 in Moderate to Severe Atopic Dermatitis Patients
The purpose of this study is to determine whether orally administered DS107 (1g and 2g doses) is effective in the treatment of moderate to severe atopic dermatitis.
- Trial name
- NCT02864498
- Testing
- DS107
- Where
- 2 sites in United States, South Africa
- Volunteers
- 321 people
- Sponsor
- DS Biopharma
Atopic Dermatitis
Clinical Study to Evaluate the Efficacy and Safety of Desoximetasone (DSXS) With Atopic Dermatitis
Efficacy and Safety of DSXS (Taro Pharmaceuticals, U.S.A., Inc.) in Patients with Moderate to Severe Atopic Dermatitis
- Trial name
- NCT02595073
- Testing
- DSXS
- Where
- United States
- Volunteers
- 124 people
- Sponsor
- Sun Pharmaceutical Industries, Inc.
Atopic Dermatitis Eczema
Trial of PDE4 Inhibition With Roflumilast for the Management of Atopic Dermatitis (INTEGUMENT-II)
This study will assess the safety and efficacy of ARQ-151 cream vs vehicle applied once a day for 4 weeks by subjects with atopic dermatitis (eczema).
- Trial name
- NCT04773600
- Testing
- Roflumilast Cream, Vehicle cream
- Where
- 53 sites in United States, Canada
- Volunteers
- 683 people
- Sponsor
- Arcutis Biotherapeutics, Inc.
Atopic Dermatitis
A Study to Learn How Different Forms of the Study Medicine Called PF 08049820 Are Taken up Into the Bloodstream in Healthy Adults
The purpose of this study is to see how different forms of a medicine called PF-08049820 move through the body when taken by mouth.
- Trial name
- NCT07172321
- Testing
- PF-08049820 MR1, PF-08049820 MR2, PF-08049820 IR
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Pfizer
Atopic Dermatitis
Evaluation of the Efficacy of Topialyse Baume barrière on Atopic Dermatis
The purpose of this study is to evaluate the efficacy and tolerability of a new SVR care product and to evaluate the reduction of the topical corticosteroids' consumption with this emollient care.
- Trial name
- TOPIA (NCT05006300)
- Testing
- Topialyse Baume Barrière
- Sponsor
- SVR Group
Atopic Dermatitis
A Study of Lebrikizumab (LY3650150) With/Without Topical Corticosteroid Treatment in Participants With Moderate-to-Severe Atopic Dermatitis
The main purpose of this study is to evaluate the efficacy and safety of lebrikizumab with/without Topical Corticosteroid Treatment in Participants with Moderate-to-Severe Atopic Dermatitis.
- Trial name
- NCT06280716
- Testing
- Lebrikizumab, Topical Corticosteroid
- Where
- 46 sites in China, South Korea
- Volunteers
- 301 people
- Sponsor
- Eli Lilly and Company
Atopic Dermatitis
A Study to Assess the Efficacy and Safety of Dupilumab in Participants With Severe Atopic Dermatitis (AD) That Are Not Controlled With Oral Cyclosporine A (CSA) or for Those Who Cannot Take Oral CSA Because it is Not Medically Advisable
The main objective of the trial is to evaluate the efficacy of 2 dose regimens of dupilumab compared to placebo, administered with concomitant topical corticosteroids (TCS), in adult patients with severe AD who are not adequately…
- Trial name
- NCT02755649
- Testing
- Dupilumab
- Where
- 73 sites in Austria, Belgium and 8 more
- Volunteers
- 325 people
- Sponsor
- Regeneron Pharmaceuticals
Eczema, Atopic Dermatitis
A Study of B244 Delivered as a Topical Spray to Assess Safety in Pediatric Subjects With Atopic Dermatitis
An open-label, multicenter, Phase Ib study of B244 delivered as a topical spray to assess safety in pediatric subjects aged 2 to 17 years with atopic dermatitis Condition or disease Intervention/treatment Phase Atopic Dermatitis…
- Trial name
- NCT03775434
- Testing
- Experimental: B244
- Where
- 6 sites in United States
- Volunteers
- 28 people
- Sponsor
- AOBiome LLC
Atopic Dermatitis
Study of CM310 in Adolescent Subjects With Atopic Dermatis
This is a multi-center, single arm, open label phase 3 study to evaluate the safety and efficacy of CM310 in children patients with moderate-to-severe atopic dermatitis.
- Trial name
- NCT06495229
- Testing
- CM310
- Where
- China
- Volunteers
- 180 people
- Sponsor
- Keymed Biosciences Co.Ltd
Atopic Dermatitis
A Clinical Study to Evaluate the Safety and Efficacy of a Baby Cleanser and a Moisturizer
A Clinical Study to Evaluate the Safety and Efficacy of a Baby Cleanser and a Moisturizer Under the Supervision of Dermatologist and Pediatrician
- Trial name
- NCT03719742
- Testing
- Sponsor Test Products
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Burt's Bees Inc.
Atopic Dermatitis
Phase 2a Study of Efficacy and Safety of OpSCF in Moderate to Severe AD (Atopic Dermatitis)
The purpose of this study is to determine the efficacy and safety of a monoclonal antibody, OpSCF, in the treatment of adults with moderate to severe Atopic Dermatitis (Eczema). OpSCF will be compared to a placebo.
- Trial name
- NCT06101823
- Testing
- OpSCF
- Where
- 22 sites in United States, Canada
- Volunteers
- 50 people
- Sponsor
- Insmed Incorporated
Atopic Dermatitis
A Safety, Tolerability and Pharmacokinetic Study of LEO 29102 in Subjects With Atopic Dermatitis
The purpose of this study is to evaluate the safety, tolerability and pharmacokinetics of 7 days treatment with LEO 29102 in adult patients with atopic dermatitis.
- Trial name
- NCT01005823
- Testing
- LEO 29102 cream
- Where
- Netherlands
- Volunteers
- 36 people
- Sponsor
- LEO Pharma
Atopic Dermatitis
Long-term Trial of OPA-15406 Ointment in Adult and Pediatric Patients With Atopic Dermatitis
To demonstrate the safety of 1% OPA-15406 ointment in adult patients with AD and of 0.3% and 1% OPA-15406 ointments in pediatric patients with AD administered twice daily for 52 weeks.
- Trial name
- NCT03961529
- Testing
- 0.3% OPA-15406 ointment, 1% OPA-15406 ointment
- Where
- Japan
- Volunteers
- 366 people
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
Atopic Dermatitis
A Study to Observe How Pediatric Patients With Severe Atopic Dermatitis Despite Less Extensive Skin Lesions Respond to Dupilumab Treatment
In adolescents treated with dupilumab, clinical trials showed significant improvement of atopic dermatitis (AD) signs and symptoms, with a good safety profile.
- Trial name
- AD-BEASCUITS (NCT06192563)
- Testing
- Dupilumab
- Where
- 9 sites in Italy
- Volunteers
- 230 people
- Sponsor
- Sanofi
Dermatitis, Atopic
Study to Investigate the Efficacy and Safety of Dupilumab Administered With Topical Corticosteroids (TCS) in Participants ≥6 to <12 Years With Severe Atopic Dermatitis (AD)
The main objective of the trial is to demonstrate the efficacy of dupilumab administered concomitantly with topical corticosteroids (TCS) in participants ≥6 years to <12 years of age with severe atopic dermatitis (AD).
- Trial name
- NCT03345914
- Testing
- Dupilumab, Background Treatment: Topical Corticosteroids, Background Treatment: Moisturizers
- Where
- 61 sites in United States, Canada and 4 more
- Volunteers
- 367 people
- Sponsor
- Regeneron Pharmaceuticals
Hand Dermatoses
Safety and Efficacy of a Retinoid for the Treatment of Severe Chronic Hand Dermatitis
Patients with severe chronic hand dermatitis, that has not responded to topical treatment, including topical steroids and the avoidance of aggravating factors, will be treated with the oral medication alitretinoin.
- Trial name
- NCT00309621
- Testing
- alitretinoin
- Where
- 33 sites in Canada, Germany and 1 more
- Volunteers
- 250 people
- Sponsor
- Basilea Pharmaceutica
Dermatitis, Atopic Dermatitis
Efficacy and Safety Study of Apremilast in Subjects With Moderate to Severe Atopic Dermatitis
A study to evaluate the efficacy and safety of apremilast (CC-10004) in subjects with moderate to severe atopic dermatitis
- Trial name
- NCT02087943
- Testing
- Apremilast
- Where
- 31 sites in United States, Canada and 1 more
- Volunteers
- 191 people
- Sponsor
- Amgen
Atopic Dermatitis
Assessment of the Effect of Coconut and Sunflower Seed Oil Derived Isosorbide Diseters and Colloidial Oatmeal
The goal of this study is to compare coconut oil and sunflower seed oil derived isosorbide disesters and colloidal oatmeal, and observe their effect on pediatric atopic dermatitis among males and females aged 2-17.
- Trial name
- NCT05688735
- Testing
- Isosorbide Diester Moisturizer, Control Moisturizer
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Integrative Skin Science and Research
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.